Arbutus regains rights to hepatitis B asset in China; Forte’s $75M offering

Plus, news about the Novo Nordisk Foundation, Assembly Biosciences, Cidara Therapeutics, Minovia and Celyad Oncology: Arbutus reacquires China rights to hepatitis B candidate: The company licensed the rights to imdusiran in ...

Related Posts

UK biotech Juvenescence targets $150M+ for 'healthy lif...

May 21, 2025  0

Shutting down a dementia care startup

May 21, 2025  0

Endpoints livestream: RFK Jr. fired the CDC's vaccine p...

Jun 10, 2025  0

Comments

Name

Email

Comment

Post Comment